Applications For The Salix Gastrointestinal Health Scholars
Program Will Be Accepted Beginning Nov. 1, 2019
BRIDGEWATER, N.J., Oct. 30, 2019 /CNW/ -- Bausch Health Companies
Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix
Pharmaceuticals ("Salix"), one of the largest specialty
pharmaceutical companies in the world committed to the prevention
and treatment of gastrointestinal (GI) diseases, today announced
the start of the applications period for its inaugural Salix
Gastrointestinal Health Scholars Program, which will award a total
of $100,000 in scholarships to ten
outstanding students living with GI disease who are pursuing their
higher education goals.
"At Salix, we are dedicated to continuous innovation in order to
address the unmet needs of patients. We are honored to launch a
scholarship program that is uniquely focused on helping students
who are living with a GI disease," said Nicola Kayel, vice president of Marketing, Salix
Pharmaceuticals.
To apply for the scholarship, a student is required to write an
essay that describes the impact having a diagnosed GI condition has
had on his or her life, as well as the role that a health care
provider played in helping to treat the condition. Scholarships are
open to school applicants or current attendees of a two- or
four-year college, university, or an advanced (post-high school)
vocational or technical school, and are available in four
categories:
- Undergraduate Scholar Awards for students pursuing
undergraduate degrees
- Graduate Scholar Awards for students pursuing graduate
degrees
- Working Parent's Scholar Award for students who are
parents pursuing undergraduate, vocational/technical or graduate
degrees
- Single Parent's Scholar Awards for students who are
single parents pursuing undergraduate, vocational/technical or
graduate degrees
Students can apply for the Salix Gastrointestinal Health
Scholars Program beginning Nov. 1,
2019 through March 1, 2020.
Winners will be announced in May
2020. To learn more about the scholarship, including
eligibility criteria, terms and conditions, please visit
www.salix.com/scholarship.
The Salix Gastrointestinal Health Scholars Program Scholarship
program is funded through the Bausch Foundation, which was
established in 2017 to improve the lives of patients globally by
providing access to safe, effective medicines and by financially
supporting health care education and causes around the world.
About Salix
Salix Pharmaceuticals is one of the
largest specialty pharmaceutical companies in the world committed
to the prevention and treatment of gastrointestinal diseases. For
30 years, Salix has licensed, developed, and marketed innovative
products to improve patients' lives and arm healthcare providers
with life-changing solutions for many chronic and debilitating
conditions. Salix currently markets its product line to U.S. health
care providers through an expanded sales force that focuses on
gastroenterology, hepatology, pain specialists and primary care.
Salix is headquartered in Bridgewater,
N.J.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Bausch Health's
most recent annual or quarterly report and detailed from time to
time in Bausch Health's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. In addition,
certain material factors and assumptions have been applied in
making these forward-looking statements, including that the risks
and uncertainties outlined above will not cause actual results or
events to differ materially from those described in these
forward-looking statements. Bausch Health believes that the
material factors and assumptions reflected in these forward-looking
statements are reasonable, but readers are cautioned not to place
undue reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
Health undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
SAL.0199.USA.19
©2019 Salix Pharmaceuticals or its affiliates.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
|
Karen Paff
|
|
karen.paff@salix.com
|
|
(908)
927-1190
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/salix-pharmaceuticals-announces-inaugural-scholarship-program-to-commemorate-its-30th-anniversary-300947754.html
SOURCE Bausch Health Companies Inc.